Cybin Inc. has been upgraded to a Buy rating due to favorable recent regulatory and clinical developments for its lead drug candidate, HLP003. The drug is benefiting from expedited FDA review processes and growing institutional support, particularly for treating major depressive disorder and PTSD. Despite these positives, the market currently undervalues Cybin, with its stock trading near cash value. Key upcoming catalysts include Phase 2/3 trial results for HLP003, progress on another candidate HLP004, and pivotal Phase 3 data expected in late 2026.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
California American Water and Sonoma County Fire District completed projects reducing wildfire risk around water facilities in Sonoma County. The efforts included clearing flammable vegetation near critical infrastructure like water storage tanks and...
